uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease

U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for ifezuntirgene inilparvovec (eye-feh-ZUN teer-JEEN in-il-par-VOE-vek) (also referred to as AMT-130), an investigational gene therapy candidate for the treatment of Huntington’s disease, for review